BOSTON, Sep 30, 2015 (BUSINESS WIRE) — On September 30, 2015, Tekla Life Sciences Investors paid a quarterly stock distribution of $0.58 per share. It is currently estimated that $0.4466 of this distribution is derived from short-term capital gains and $0.1334 of this distribution is derived from long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $279,398,058, of which $ 193,676,478 represents net unrealized appreciation of portfolio securities.
The following table sets forth the estimated amounts of the current distribution, paid September 30, 2015, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains, and return of capital or other capital source. All amounts are expressed per common share.
|Current Distribution||Percentage Breakdown of
|Total Cumulative Distributions for the
Fiscal Year to Date1
|Percentage Breakdown of the Total Cumulative
Distributions for the
Fiscal Year to Date1
|Net Investment Income||$0.0000||0%||$0.0000||0%|
|Net Realized ST Cap Gains||$0.4466||77%||$1.1316||54%|
|Net Realized LT Cap Gains||$0.1334||23%||$0.9584||46%|
|Return of Capital or OtherCapital Source||$0.0000||0%||$0.0000||0%|
|TOTAL (per common share):||$0.5800||100%||$2.0900||100%|
The table below includes information relating to Fund’s performance based on its NAV for certain periods.
|Average annual total return at NAV for the period from July 31, 2010 through July 31, 2015||32.64%|
|Annualized current distribution rate expressed as a percentage of NAV as of July 31, 2015||7.79%|
|Cumulative total return at NAV for the fiscal year, through July 31, 20152||34.60%|
|Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of July 31, 2015||7.02%|
You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution plan.
The amounts and sources of distributions reported in this press release are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.
Tekla Life Sciences Investors HQL, +5.58% is a closed-end fund that invests in companies in the life sciences industry.
Tekla Capital Management LLC, the Fund’s investment adviser, is a Boston, MA based healthcare-focused investment manager with approximately $3.4 billion of assets under management as of June 30, 2015. Tekla also serves as investment adviser to Tekla Healthcare Investors HQH, +5.87%Tekla Healthcare Opportunities Fund THQ, +2.84% and Tekla World Healthcare Fund THW, -0.83% closed-end funds that invest in companies in the healthcare industry.
For information please visit www.teklacap.com or call (617) 772-8500.
1 The Fund’s current fiscal year began on October 1, 2014.
2 Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2014 through July 31, 2015.
Source: Tekla Life Sciences Investors
After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.
Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.
UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.